figs3.

AOPPs activated ERK1/2 and p38 MAPK in IEC-6 cells. IEC-6 cells were treated with 200μg/ml of AOPPs for the time periods indicated (a) or pretreated with a MEK1/2 inhibitor (U0126) and a p38 MAPK inhibitor (SB203580), all at 10μM, for 1h and subsequently incubated with 200μg/ml of AOPPs for 24h (b). (a) Representative Western blotting and densitometry quantification showed that AOPPs enhanced the phosphorylation of ERK1/2 and p38 MAPK in IEC-6 cells in a time-dependent manner. (b) Flow cytometry revealed that the ERK1/2 and p38 MAPK inhibitors had no effect on the AOPPs-induced G1 phase arrest in IEC-6 cells. The bar graph illustrates the percentage of cells in G1. Data are presented as mean ± SD from three independent experiments; error bars indicate SD. **P<0.01 versus control. +U0126, AOPPs plus an inhibitor of MEK1/2 treatment; + SB203580, AOPPs plus an inhibitor of p38 MAPK treatment.